[Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].

曲妥珠单抗 不利影响 医学 内科学 癌症 乳腺癌
出处
期刊:PubMed [National Institutes of Health]
卷期号:46 (4): 304-318 被引量:2
标识
DOI:10.3760/cma.j.cn112152-20231122-00319
摘要

Trastuzumab deruxtecan (T-DXd) is one of the new generation antibody-drug conjugates (ADCs) targeting human epidermal growth factor receptor 2 (HER-2) with bystander effect. T-DXd can not only significantly improve the survival of HER-2-positive advanced breast cancer patients, but also enable advanced breast cancer patients with low HER-2 expression to benefit from HER-2-targeted therapy. T-DXd has been approved by the National Medical Products Administration (NMPA) for the treatment of HER-2-positive or HER-2-low breast cancer patients. It is foreseeable that T-DXd will be widely used in clinical practice in the future. However, T-DXd has also shown different safety characteristics compared to previous HER-2 targeted drugs in clinical trials. How to manage T-DXd adverse events more reasonably and fully utilize the efficacy of T-DXd is an urgent clinical problem. Based on the existing clinical evidence and guideline consensus, combined with clinical practice experience, the expert group finally reached the consensus of clinical care pathway and adverse reaction management of trastuzumab deruxtecan after many discussions. This consensus content includes the clinical use method of T-DXd, pre-treatment patient education, and management of common or noteworthy adverse events of T-DXd. The adverse events include infusion related adverse events, digestive system adverse events (nausea/vomiting, constipation, diarrhea, and decreased appetite), hematological adverse events (neutropenia, febrile neutropenia, anemia, thrombocytopenia), respiratory adverse events (interstitial lung disease/pneumonia), cardiovascular adverse events (decreased left ventricular ejection fraction), adverse events in liver function (elevated transaminases) and other common adverse events (alopecia, fatigue, etc). This consensus focuses on the prevention of adverse events, dose adjustment and treatment when adverse events occur, and recommendations for patients' lifestyle, aiming to improve clinicians' understanding of T-DXd and provide practical guidance for clinical oncologists on T-DXd clinical management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
红莲墨生发布了新的文献求助10
1秒前
1秒前
阿皮发布了新的文献求助10
2秒前
2秒前
zjj关注了科研通微信公众号
3秒前
ppzzqq123发布了新的文献求助10
4秒前
GGbond完成签到,获得积分10
5秒前
黑米粥发布了新的文献求助200
5秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
充电宝的应助被科研通管家采纳,获得10
6秒前
斯文败类的应助被科研通管家采纳,获得10
6秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
Jasper的应助被南歪歪采纳,获得10
6秒前
桐桐的应助被科研通管家采纳,获得10
6秒前
6秒前
英姑的应助被科研通管家采纳,获得10
7秒前
Wenlia的应助被科研通管家采纳,获得10
7秒前
852的应助被科研通管家采纳,获得10
7秒前
DW的应助被科研通管家采纳,获得10
7秒前
诸葛明明的应助被科研通管家采纳,获得10
7秒前
我是老大的应助被科研通管家采纳,获得10
7秒前
田様的应助被科研通管家采纳,获得10
7秒前
DW的应助被科研通管家采纳,获得30
7秒前
bkagyin的应助被科研通管家采纳,获得10
8秒前
丘比特的应助被科研通管家采纳,获得10
8秒前
Irene发布了新的文献求助10
8秒前
8秒前
隐形曼青的应助被yang采纳,获得10
8秒前
8秒前
8秒前
TED的应助被科研通管家采纳,获得10
8秒前
AireenBeryl531举报糊涂塌客的求助涉嫌违规
8秒前
Owen的应助被科研通管家采纳,获得10
8秒前
JULY发布了新的文献求助10
8秒前
8秒前
搜集达人的应助被科研通管家采纳,获得10
9秒前
TED的应助被科研通管家采纳,获得10
9秒前
极限001的应助被科研通管家采纳,获得50
9秒前
ForTune完成签到,获得积分10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846